相关实验视频
Updated: Jan 18, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
提亚-提亚化合物用于酶调节和治疗向糖尿病患者的治疗
Shoaib Khan1, Tayyiaba Iqbal1, Sobhi M Gomha2
1Department of Chemistry, Abbottabad University of Science and Technology, Abbottabad, Pakistan.
Chemistry & biodiversity
|September 9, 2025
概括
科学家们开发了新的醇衍生型亚醇基希夫基作为潜在的抗糖尿病药物. 同类药物8,5和9显示出对糖尿病的显著抑制潜力,优于参考药物阿卡尔.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是一种日益严重的全球健康问题,随着药物耐药性的增加.
- 对于新型,强效的抗糖尿病化合物有着至关重要的需求.
- 来自 thiazole 和 thiadiazole 支架的 Schiff 基被探索治疗潜力.
研究的目的:
- 合成和表征一种新型的亚醇基希夫基衍生物的亚醇基衍生物系列.
- 评估这些合成化合物的体外抗糖尿病抑制潜力.
- 调查最有前途的候选者的分子相互作用和药理学概况.
主要方法:
- 使用已确定的有机化学技术合成化合物1-10.
- 通过核磁共振 (1H NMR, 13C NMR) 和高分辨率电喷射电离化质谱法 (HREI-MS) 进行结构阐明.
- 在体外酶抑制对α-葡萄糖酶的测定,与acarbose相比.
- 分子对接,分子动力学模拟,ADMET预测和密度函数理论 (DFT) 分析.
主要成果:
- 一系列由十种新型的亚醇衍生型亚醇基希夫基衍生物成功合成和表征.
- 化合物8,5和9表现出强大的α-葡萄糖酶抑制活性,IC50值分别为4.20 ± 0.10,5.10 ± 0.30,6.20 ± 0.10μM,超过了参考药物阿卡尔 (IC50 = 7.50 ± 0.10μM).
- 分子对接和动力学模拟为结合相互作用和构造稳定性提供了洞察力,而ADMET分析表明了有利的安全概况,DFT分析阐明了电荷分布和反应性.
结论:
- 合成的醇衍生型亚醇基希夫基代表了开发新型抗糖尿病疗法的有前途的化合物类别.
- 化合物8,5,和9被确定为主要候选物,因为它们具有优越的抑制活性和有利的预测药理特性.
- 需要进一步的体内研究来验证这些新型抗糖尿病药物的治疗潜力.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
Oral Hypoglycemic Agents: Sulfonylureas
798
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
798
Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
Antihypertensive Drugs: Thiazide-Class Diuretics
1.6K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Dipeptidyl Peptidase 4 Inhibitors
598
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598
